Endoplasmic Reticulum aminopeptidase 1 and 2 are two homologous enzymes that
help generate peptide ligands for presentation by Major Histocompatibility Class I molecules.
Their enzymatic activity influences the antigenic peptide repertoire and indirectly controls
adaptive immune responses. Accumulating evidence suggests that these two enzymes are tractable
targets for the regulation of immune responses with possible applications ranging from
cancer immunotherapy to treating inflammatory autoimmune disease. Here, we review the
state-of-the-art in the development of inhibitors of ERAP1 and ERAP2 as well as their potential
and limitations for clinical applications.
Keywords: aminopeptidase, antigen processing and presentation, peptide, inhibitor, cancer, autoimmunity, infection, MHC, antigen.
Rights & PermissionsPrintExport